Search

Bristol-Myers Squibb Co.

Nyitva

SzektorEgészségügy

63.7 -0.59

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

63.12

Maximum

64.41

Fő mutatók

By Trading Economics

Bevétel

638M

3.3B

Értékesítés

1.5B

13B

P/E

Szektor átlag

14.718

56.597

Egy részvényre jutó nyereség

2.04

Osztalékhozam

3.69

Profit margin

25.561

Munkavállalók

32,500

EBITDA

1.3B

4.9B

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+4.26% upside

Osztalékok

By Acuity

Osztalékhozam

Szektor átlag

3.69%

2.18%

Következő eredményjelentés

2026. okt. 29.

Következő korábbi osztalék dátum

2026. okt. 2.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

8.7B

136B

Előző nyitás

64.29

Előző zárás

63.7

Hangulat hírek alapján

By Acuity

37%

63%

73 / 339 Rangsor szerint Healthcare

Bristol-Myers Squibb Co. Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 14. 19:26 UTC

Correlated Moves

Advancing amid favorable market conditions, State Street Health Care ETF rises.

2026. szept. 10. 19:16 UTC

News

Bristol-Myers Squibb shares are lower as HSBC raises price target to $65.00 while maintaining a Hold rating amid ongoing market sentiment.

2026. szept. 9. 23:01 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, marking a potential rebound after three sessions of declines. No specific news was identified.

2026. szept. 8. 23:06 UTC

Event

Bristol-Myers Squibb Co reported positive Phase 2 trial results for arlocabtagene autoleucel, contributing to shares advancing in after-market trading.

2026. szept. 4. 22:14 UTC

Correlated Moves
Social Media

Bristol-Myers Squibb Co shares are lower in after-market trading following the FDA's withdrawal of Krazati's accelerated approval for colorectal cancer.

2026. szept. 3. 21:51 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, declining since Thursday's close amid a broader market rally and no specific company news.

2026. szept. 2. 23:01 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours. Broader market sentiment is affected by rising oil prices amid U.S.-Iran tensions.

2026. szept. 1. 23:06 UTC

Correlated Moves

Bristol-Myers Squibb shares declined after market close, mirroring a broader downturn in the pharmaceutical sector amid rising oil prices and inflation concerns.

2026. aug. 31. 20:07 UTC

News
Social Media
Correlated Moves
Event

Bristol-Myers Squibb shares are higher following positive long-term data on Camzyos presented at the European Society of Cardiology Congress, showing significant patient improvements.

2026. aug. 28. 23:01 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, rebounding from three consecutive lower sessions with no specific news identified.

2026. aug. 27. 19:36 UTC

Bristol-Myers Squibb shares are lower today amid broader market concerns over rising inflation and potential Federal Reserve interest rate hikes.

2026. aug. 26. 23:16 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news identified to explain the decline following a routine session.

2026. aug. 25. 23:21 UTC

Correlated Moves

Bristol-Myers Squibb Co shares are lower in after-market trading, influenced by a decline in the pharmaceutical sector and falling crude oil prices.

2026. aug. 24. 23:41 UTC

Bristol-Myers Squibb shares are trading lower in after-market hours amid weak market conditions and heightened geopolitical tensions affecting overall investor sentiment.

2026. aug. 21. 20:02 UTC

Social Media

Bristol-Myers Squibb Co is higher today following reports of a collaboration with Chai on antibody discovery, enhancing its drug development capabilities.

2026. aug. 20. 20:01 UTC

News

Bristol-Myers Squibb shares are lower amid a significant decline in the Pharmaceuticals sub-sector, despite recent FDA approval for its multiple myeloma drug.

2026. aug. 19. 23:21 UTC

Bristol-Myers Squibb Co shares are higher in after-market hours, fluctuating between a low of -0.28% and a high of 0.50% since Wednesday's close.

2026. aug. 18. 19:46 UTC

Social Media

Bristol-Myers Squibb is using AI tools to cut clinical trial development times, trading higher amid positive market sentiment surrounding these advancements.

2026. aug. 17. 23:01 UTC

Bristol-Myers Squibb Co shares are lower in after-market trading amid broader market concerns and unusual selling pressure, though no specific news was identified.

2026. aug. 14. 20:06 UTC

Social Media
News
Event

Bristol-Myers Squibb shares are lower after FDA approval of Zenbexus due to concerns over its $29,500 pricing, which may dampen market sentiment.

2026. aug. 13. 23:56 UTC

News
Event

Bristol-Myers Squibb's shares are lower after FDA approval of ZENBEXUS for multiple myeloma, amid concerns over drug risks and ongoing trial verification.

2026. aug. 12. 23:56 UTC

Bristol-Myers Squibb Co shares rose in after-market trading following U.S. Consumer Price Index data, easing concerns about aggressive Federal Reserve interest rate hikes.

2026. aug. 11. 23:01 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, rising from earlier gains and positioned above their 20-day moving average.

2026. aug. 10. 23:51 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours. The decline follows three consecutive sessions of gains amid shifting labor market sentiment.

2026. aug. 8. 00:01 UTC

Bristol-Myers Squibb Co. shares are lower in after-market trading, continuing a decline since Friday's close despite being above the 20-day moving average.

2026. aug. 7. 23:06 UTC

Bristol-Myers Squibb shares lower in after-market trading, despite maintaining a position above the 20-day moving average. No specific news was identified.

2026. aug. 6. 23:26 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, influenced by broader market trends and a stronger U.S. Dollar amid rising jobless claims.

2026. aug. 5. 23:01 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours. No specific news was identified to explain the movement.

2026. aug. 4. 23:16 UTC

Bristol-Myers Squibb Co. shares gained in after-market trading, reflecting a modest uptick of 0.20% and remaining above their 20-day moving average.

2026. aug. 3. 23:02 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news identified to explain the movement. The stock remains above its 20-day moving average.

Társak összehasonlítása

Árváltozás

Bristol-Myers Squibb Co. Előrejelzés

Célár

By TipRanks

4.26% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 66.833 USD  4.26%

Magas 80 USD

Alacsony 40 USD

20 Wall Street elemző 12 hónapos célárain alapulva a(z)Bristol-Myers Squibb Co. termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

20 ratings

8

Vétel

11

Tartás

1

Eladás

Hangulat

By Acuity

73 / 339 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bullish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
help-icon Live chat